Better stay away from American universities.
"To see the extent of the gulf that now separates the American nomenklatura from the workers and peasants, consider the findings of a Rasmussen poll from last September, which sought to distinguish the attitudes of the Ivy Leaguers from ordinary Americans.
"The poll defined the former as “those having a postgraduate degree, a household income of more than $150,000 annually, living in a zip code with more than 10,000 people per square mile,” and having attended “Ivy League schools or other elite private schools, including Northwestern, Duke, Stanford, and the University of Chicago.”
"Asked if they would favor “rationing of gas, meat, and electricity” to fight climate change, 89 percent of Ivy Leaguers said yes, as against 28 percent of regular people. Asked if they would personally pay $500 more in taxes and higher costs to fight climate change, 75 percent of the Ivy Leaguers said yes, versus 25 percent of everyone else.
'“Teachers should decide what students are taught, as opposed to parents”' was a statement with which 71 percent of the Ivy Leaguers agreed, nearly double the share of average citizens. “Does the U.S. provide too much individual freedom?” More than half of Ivy Leaguers said yes; just 15 percent of ordinary mortals did. The elite were roughly twice as fond as everyone else of members of Congress, journalists, union leaders, and lawyers. Perhaps unsurprisingly, 88 percent of the Ivy Leaguers said their personal finances were improving, as opposed to one in five of the general population."
Dr. Niall Ferguson
The FDA has rejected its strongest safety warning for Covid mRNA vaccines despite acknowledging that children were killed by the products.
This news surfaced during a televised Bloomberg interview with FDA Commissioner Marty Makary, who said the agency has “no plans” to apply its strongest safety warning to Covid mRNA vaccines.
In that interview, Makary confirmed that the FDA’s own safety and epidemiology centre had formally recommended a boxed warning — a step reserved, under FDA rules, for drugs with “special problems, particularly ones that may lead to death or serious injury.”